- Home
- COEP vs IVVD Comparison
COEP vs IVVD Comparison
Compare COEP & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COEP
- IVVD
- Stock Information
- Founded
- COEP 2017
- IVVD 2020
- Country
- COEP United States
- IVVD United States
- Employees
- COEP N/A
- IVVD N/A
- Industry
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- COEP Health Care
- IVVD Health Care
- Exchange
- COEP Nasdaq
- IVVD Nasdaq
- Market Cap
- COEP 62.4M
- IVVD 63.4M
- IPO Year
- COEP N/A
- IVVD 2021
- Fundamental
- Price
- COEP $12.96
- IVVD $1.31
- Analyst Decision
- COEP
- IVVD Strong Buy
- Analyst Count
- COEP 0
- IVVD 4
- Target Price
- COEP N/A
- IVVD $3.64
- AVG Volume (30 Days)
- COEP 45.5K
- IVVD 15.0M
- Earning Date
- COEP 11-12-2025
- IVVD 11-13-2025
- Dividend Yield
- COEP N/A
- IVVD N/A
- EPS Growth
- COEP N/A
- IVVD N/A
- EPS
- COEP N/A
- IVVD N/A
- Revenue
- COEP $263,555.00
- IVVD $46,210,000.00
- Revenue This Year
- COEP N/A
- IVVD $385.94
- Revenue Next Year
- COEP N/A
- IVVD $62.62
- P/E Ratio
- COEP N/A
- IVVD N/A
- Revenue Growth
- COEP N/A
- IVVD 1941.08
- 52 Week Low
- COEP $2.31
- IVVD $0.35
- 52 Week High
- COEP $14.70
- IVVD $2.74
- Technical
- Relative Strength Index (RSI)
- COEP 54.10
- IVVD 65.63
- Support Level
- COEP $12.09
- IVVD $1.05
- Resistance Level
- COEP $13.53
- IVVD $1.45
- Average True Range (ATR)
- COEP 0.74
- IVVD 0.19
- MACD
- COEP -0.12
- IVVD 0.04
- Stochastic Oscillator
- COEP 56.55
- IVVD 80.81
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.